02362nab a2200241 i 4500 publ10268 20190522160647.0 170117s2016 hu o 0|| zxx d 1742-5255 10.1080/17425255.2016.1214715 doi 3137890 mtmt SZTE Publicatio Repozitórium hun zxx Dézsi Livia Intravenous immunoglobulin [elektronikus dokumentum] : pharmacological properties and use in polyneuropathies / Dézsi Livia 2016 1343-1358 EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 12 No. 11 Introduction: Intravenous immunoglobulin (IVIg) is increasingly used for the treatment of autoimmune and systemic inflammatory diseases with both licensed and off-label indications. The mechanism of action is complex and not fully understood, involving the neutralization of pathological antibodies, Fc receptor blockade, complement inhibition, immunoregulation of dendritic cells, B cells and T cells and the modulation of apoptosis. Areas covered: First, this review describes the pharmacological properties of IVIg, including the composition, mechanism of action, and adverse events. The second part gives an overview of some of the immune-mediated polyneuropathies, with special focus on the pathomechanism and clinical trials assessing the efficacy of IVIg. A literature search on PubMed was performed using the terms IVIg, IVIg preparations, side effects, mechanism of action, clinical trials, GBS, CIDP. Expert opinion: Challenges associated with IVIg therapy and the treatment possibilities for immune-mediated polyneuropathies are discussed. The availability of IVIg is limited, the expenses are high, and, in several diseases, a chronic therapy is necessary to maintain the immunomodulatory effect. The better understanding of the mechanism of action of IVIg could open the possibility of the development of disease-specific, targeted immune therapies. © 2016 Informa UK Limited, trading as Taylor & Francis Group. Horváth Zoltán aut Vécsei László aut http://publicatio.bibl.u-szeged.hu/10268/1/Dezsi_L._Intravenous_immunoglobulin_proof_u.pdf Dokumentum-elérés http://publicatio.bibl.u-szeged.hu/10268/7/Intravenous_immunoglobulin.pdf Dokumentum-elérés